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Background. We present the case of a 35-year-old gentleman who presented with an aggressive cardiomyopathy with normal
coronaryarteries.Hewaslaterdiagnosedwithsystemiclupus-relatedcardiomyopathy.Methods.Weundertookanextensivereview
of the literature regarding cardiac manifestations of lupus and used over 100 journals to identify the key points in pathology,
diagnosis, and treatment. Results. We have shown that cardiac lupus can be rapidly progressive and, unless treated early, can
have severe consequences. The predominant pathologies are immune complex and accelerated atherosclerosis drive. Treatment
comprised of high-level immunosuppression.
1. InitialReferral
A 35-year-old UK born man was referred to the cardiology
department at University Hospital Aintree in October 2009
with a few troublesome palpitations a day, which had
increased in frequency over the preceding 4 months, and
occasional dizziness.
H i sb a c k g r o u n dw a sa sal a ws t u d e n tw h ow a san o n -
smoker and consumed no alcohol. His family history re-
vealed a ﬁt and well mother, father, and sister but, interest-
ingly, two paternal uncles who had died suddenly of an
unknown cause.
His examination was unremarkable, and his ECG was
normal apart from a few isolated unifocal ventricular ec-
topics and a normal echocardiogram apart from some mild
distal inferior septal hypokinesis with an ejection fraction of
57.3% using the Simpson’s biplane method.
P l a n sw e r em a d ef o rh i mt oh a v ea no u t p a t i e n t2 4 - h o u r
tape and to be reviewed again in clinic.
2. FirstAdmission
Unfortunately, he was admitted via the emergency depart-
ment three days later with constant palpitations, dizziness,
and increasing shortness of breath. Clinically, there were no
signs of heart failure or thyroid disease.
He was found to have a Troponin T of 1.02µg/L (1.39 at
twelve hours), and his ECG showed sinus rhythm with septal
Q waves, poor septal R wave progression, and ventricular
couplets. While on telemetry, he was noted to have short
runs of ventricular tachycardia (VT) with a high background
burden of ventricular ectopics.
He was started on treatment for his heart failure and
arrhythmia comprising of bisoprolol 2.5mg, aspirin 75mg,
and ramipril 1.25mg (the dosages were maximised as far as
his blood pressure would allow).
He had a repeat echocardiogram, which revealed a
worseningofhisinferoseptalhypokinesisfrommildtosevere
and some anterior/apicoanterior hypokinesis. He was also
noted to have multiple strands/trabeculae in the LV apex.
To further investigate, a 3D echocardiogram was organ-
ised which revealed a false tendon but also hypertrabecula-
tionintheapexanda3-wayconnectionbetweentheinferior,
septal, and anterior walls. A diagnosis of LV compaction was
mooted, and his angiogram was scheduled for the next day.
A picture of the 3D echocardiogram, Figure 1 is showing
spontaneous echo contrast and trabeculations in the apex2 Cardiology Research and Practice
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Figure 1
A screen for cardiomyopathy revealed normal iron levels,
thyroid function, magnesium, zinc, ceruloplasmin, and
immunoglobulins. His angiogram revealed unobstructed
coronaries with no evidence of thrombosis and no disease
that would explain his regional wall motion abnormalities,
good compaction on ventriculography, and an ejection
fraction of 40%.
Reversible causes of cardiomyopathy were considered
and excluded, and there was no history of an infective viral
precipitant. The combination of a negative cardiomyopathy
screen so far and the lack of an infective cause, made a pro-
gressive condition most likely as his symptoms progressed.
He improved symptomatically and was seen two weeks
later by the electrophysiology team, who organised an
MRI that revealed both left and right ventricular dilatation
with moderate biventricular impairment and scarring. An
outpatient 24-hour tape revealed a sinus bradycardia with
almost 19,000 ventricular ectopics, including couplets and
triplets but no ventricular tachycardia.
An image of his cardiac MRI on 2D scar weighting is
shown in Figure 2 with scarring and biventricular dilatation.
An implantable cardiac deﬁbrillator was discussed and
the patient chose to go away and consider his options. The
option of a life vest deﬁbrillator was not considered at that
point as it was felt that the patient needed to weigh up
the eﬀect of any deﬁbrillator, and if he were to reject an
implantableversionthenthelifevestsystemwouldbeoﬀered.
His medical treatment remained the same comprising of
aspirin, bisoprolol, simvastatin, and ramipril.
3.Second Admission
He was readmitted 6 weeks later with increasing frequency of
palpitation and debilitating dizziness. During his admission,
Figure 2
he had frequent runs of VT with occasional haemodynamic
compromise before cardioverting on his own.
As the patient’s blood pressure was only ever just above
1 0 0 m m / h g ,w ew e r eu n a b l et oi n c r e a s ea n yo fh i sh e a r t
failure treatment.
He underwent left and right heart catheterisation and
endomyocardial biopsies at the local specialist centre before
he had an ICD inserted. The left heart catheter was repeated
as the team at the specialist centre felt the rapidly progressive
nature of his course merited exclusion of coronary artery
thrombus formation. The left heart catheter showed normal
coronary arteries again, and the right ventricular systolic
pressure was 25 and the pulmonary capillary wedge pressure
was 10.Cardiology Research and Practice 3
Figure 3
He improved in a short period of time with the same
medications and was discharged with followup arranged for
the results of his biopsy.
4. Third Admission
This patient was readmitted two weeks into the year 2010
with chest tightness and orthopnoea, his exercise tolerance
dropping to 50 yards. His oxygen saturations on air were
89%, and apart from a displaced apex beat there were no
signs of heart failure.
Duringthistime,hewasnotedtohavelostaconsiderable
amount of weight and to have developed a widespread
myopathy. He had an autoimmune screen, which was
positive for anti-RO and LA antibodies with an ANA titre
of 1:640 with a membrane speckling pattern and a CK of
10,000. His lupus coagulant and anticardiolipin antibodies
were negative. His forced vital capacity was normal at 5.8l.
CT pulmonary angiography was negative.
The histology of his cardiac biopsy revealed extensive
myocardiolysis and interstitial ﬁbrosis with no abnormal
staining for amyloid or iron, a result suggestive of ischaemia
consistent with a possible diagnosis of SLE. He went on
to have a muscle biopsy, which showed widespread skeletal
muscle necrosis. His genetic tests for the various types of
muscular dystrophy were negative.
Histology of his cardiac biopsy, showing ﬁbrosis in
between the few surviving myocardial ﬁbres, is shown in
Figure 3.
He had his echocardiogram repeated, and all his cham-
bers had become dilated with severely impaired LV and RV
function with spontaneous echo contrast and an ejection
fraction of 16%. His pulmonary artery pressure was 9.4 plus
right atrial pressure. This reduction had occurred over a
period of 3 months. As a result of severe cardiac impairment
and the presence of spontaneous echo contrast, he had
his aspirin replaced with warfarin to cover for the high
thromboembolic risk.
He continued on the ramipril 1.25mg, bisoprolol 2.5mg
with furosemide 40mg bd, and spironolactone 25mg with
warfarin added. Unfortunately, despite the maximum anti-
heart failure treatment his blood pressure would tolerate, he
did not make any signiﬁcant improvement
5. Most Recent Admission
He was readmitted two weeks after his most recent discharge
again with worsening shortness of breath and fatigue.
After a multidisciplinary discussion with neurology and
rheumatology, a diagnosis of systemic lupus erythematosus
(SLE) was made, and he was put on high-dose steroids
and given a short course of immunoglobulins. He improved
clinically with a larger appetite, better mobility, and a
reduction in his CK to only 3000.
He was given 6 cycles of outpatient cyclophosphamide
before being put on maintenance Azathioprine 100m/day in
addition to his existing treatment. Aggressive immunosup-
pressives helped clinically, and there was a small improve-
ment in his end diastolic diameters and an improvement in
his ejection fraction by 2%. As the antiheart-failure treat-
ment remained the same, it was felt that the improvement
in his echo parameters was due to his immunosuppression.
6. Current Condition
Mr. A has begun to deteriorate once again and is currently
being seen by both the transplant and rheumatology teams
to see what the beneﬁts and risks of cardiac transplant would
be.
7.Review Methodology
Three reviewers undertook literature searches using PubMed
andMEDLINEwithsearchtermsincluding SLEmyocarditis,
SLE cardiomyopathy, SLE with cardiac involvement, treat-
mentofSLEcardiomyopathy,andcardiac/hearttransplantin
SLE. Lupus replaced SLE in all the above searches in a second
round to ensure maximum data collection. We excluded
animal studies work on patients under 18, and studies which
did not focus on the cardiac manifestations of SLE. There
were no date restrictions, and only articles in English were
used for the review.
Over 100 articles were identiﬁed and were then systemat-
icallyreviewedtoextrapolateimportantapplicablepointsfor
future use in four key areas: pathology, imaging, treatment,
and transplant.
8. Discussion
We present below a review of the literature as SLE cardiomy-
opathy carries a signiﬁcant mortality risk over SLE without
cardiac involvement [1], but it is important to remember
that all cardiomyopathy has a poor prognosis with studies
looking at cardiomyopathy not related to coronary artery
disease having a 5-year mortality of 20% [2].
We will now look systematically at the incidence, diag-
nosis, treatment, and outcomes in SLE with cardiac involve-
ment.4 Cardiology Research and Practice
8.1. Incidence and Prevalence. SLE is one of the most
common multisystem autoimmune disorders in the world
with a variable prevalence but when investigated a preva-
lence of 51/100000 in 2003 [3]. The male-female ratio is
approximately 9:1 with a higher incidence in people of a
non-Caucasian background [4].
The incidence of cardiac involvement at postmortem is
approximately forty percent, but only six percent of patients
had echocardiographic evidence of impairment, and only 1
death in a cohort of over 500 patients was attributable to
cardiac involvement [5].
8.2. Diagnosis of SLE: A Noncardiac Perspective. The diag-
nosis of SLE without the advantage of biopsy specimens
remains based on the 1997 update from the American
College of Rheumatologists and is based on four positive
criteria out of eleven [6]r e p r o d u c e db e l o w :
(1) malar rash,
(2) discoid rash,
(3) photosensitivity,
(4) oral ulcers,
(5) nonerosive arthritis,
(6) pleuritis or pericarditis,
(7) renal disorder,
(8) neurological disorder,
(9) haematological disorder,
(10) immunological disorder, for example, positive anti-
bodies to DS-DNA, SM, or phospholipids,
(11) positive ANA.
As many patients do not make it as far as a deﬁnitive biopsy,
diagnosisremainsbasedonacombinationofclinicalfeatures
and immunological phenomena as described in the above
guidelines.
8.3. Cardiac Pathology in SLE. There are a number of
possible cardiac manifestations of SLE, the most common
forms being pericarditis, myocarditis, nonbacterial verru-
cousendocarditis,coronaryarterydisease,coronaryarteritis,
premature coronary atherosclerosis, congestive heart failure,
cardiac arrhythmias, pulmonary hypertension, and conduc-
tion disturbances.
Symptoms and severity of the disease are linked to the
pattern of autoantibodies expressed, in addition, the inter-
individual variable expression of antibodies to ds-DNA, Ro,
or anticardiolipin, permit a subtyping of SLE and indicate
that there may well be great overlapping of SLE and other
conditions such as dermatomyositis, progressive systemic
sclerosis, or Sj¨ ogren’s syndrome.
SLE manifests as we see above in many ways, but we will
focus on myocardial disease and accelerated atherosclerosis,
as they constitute the major primary cardiac problems.
SLE is the classical example of an immune complex
(IC) associated systemic autoimmune disease, and that
this immune complex deposition results in an inﬂam-
matory response involving the myocardium, pericardium,
and perivascular tissue of cardiac blood vessels [7]. This
inﬁltration by immune complexes leads to complement
activation and a generalised polymorph invasion followed by
myocardial damage [8].
The other major manifestation that we will consider is
accelerated atherosclerosis, and it has been with approx-
imately ﬁfty percent of all suﬀerers having signiﬁcant
atherosclerosis at postmortem [9]. The underlying mecha-
nismisthoughttobesimilartothatofthegeneralpopulation
but at an accelerated rate due to inﬂammatory endothelial
dysfunction [8].
The medications involved in treating SLE may also con-
tribute, such as azathioprine-induced endothelial dysfunc-
tion [8]. There are also some suggestions as with our patient
that there is an alteration of coronary microcirculation
leading to ischaemic damage with normal coronaries on
angiography similar to our patient.
8.4. Cardiac Imaging in SLE. Before we can begin on imag-
ing, the key ﬁrst step in investigation of SLE-related cardiac
disease is the electrocardiogram for analysis of arrhythmias,
ischaemic change, and left ventricular function.
While there is no particular consensus on what imaging
is required when cardiac involvement with SLE is suspected,
the most reasonable ﬁrst step is echocardiography as with
many cardiac diseases. Echocardiography can help diag-
nose SLE-related pericarditis, systolic dysfunction, valvu-
lar involvement, and cavity thrombus formation with a
good sensitivity [10]. While transthoracic echocardiography
is more than acceptable in routine practice, sometimes
transesophageal echocardiography may be needed for closer
analysis of valve structure and function and is thus more
sensitive [11]. 3D echocardiography does not really add
much to diagnosis except for exclusion of other types of
cardiomyopathy such as noncompaction cardiomyopathy.
The next step in investigation, we would suggest, in
patients with cardiomyopathy and SLE is coronary angiogra-
phyastherateofatherosclerosisismarkedlyraisedcompared
to control subjects [12]. This is based on the fact that
there can be thrombus within the coronary arteries but the
main step is to look for signiﬁcant coronary artery disease
causing ischaemia, as this is the most common factor for
cardiomyopathy in normal people and myocardial infarction
rates are ﬁfty-times higher in SLE [13].
Other imaging modalities have been used to look for
ischaemia such as myocardial perfusion scanning [14],
cardiac CT angiography [15], and stress echocardiography
[16]. As these techniques and cardiac MRI angiography
becomemorewidespreadinclinicalpractice,wefeeltheywill
to a large extent, replace invasive angiography.
If angiography has shown normal coronary arteries and
there is evidence of an SLE cardiomyopathy process, then
magnetic resonance imaging should be undertaken to look
for changes in structure such as ﬁbrosis and scarring, and in
some cases MRI has been used to check function in patients
who have clinically improved [17].Cardiology Research and Practice 5
Endomyocardial biopsy for attempted deﬁnitive histo-
logical diagnosis despite the risks and potentially low yield
is still widely recommended [8], and at least ﬁve right
ventricular samples have been recommended [18]. It is
important to say that biopsy is mainly used to diﬀerentiate
between SLE myocarditis and antimalarial-induced damage,
and in a previously published case series of 58 patients with
endomyocardial biopsies in SLE-related cardiomyopathy,
38% percent were diagnostic of lupus-induced damage, 22%
of drug related damage, and 29% nonspeciﬁc.
Histological features of SLE cardiomyopathy may be
nonspeciﬁc to some degree, but there are some important
typical features to be aware of which include initially inﬂam-
matory cell inﬁltrates, for example CD 68 macrophages,
which can be identiﬁed using immunohistochemistry [8]. As
the disease advances, there is myocardial necrosis, ﬁbrotic
replacement, and scarring, all features seen in our patient’s
histology.
In the end, the variable diagnostic yield nature of endo-
myocardialcombinedwiththesometimesnonspeciﬁcnature
of the disease means that diagnosis must be a balanced clin-
ical decision taking into account the history, examination,
immunology, imaging, and, if possible, histology.
8.5. Treatment of Cardiac SLE
8.5.1. Medical Management. While SLE causes a wide range
of cardiovascular diseases, the complication should be dealt
with in the standard fashion, that is, angiotensin-converting
enzyme inhibitors, beta-blocker for left ventricular impair-
ment, and coronary stenting for stenoses.
Reviewing the literature, the most common immuno-
suppressive treatment choice for acute ﬂares seems to be
high-dose steroids followed by pulsed cyclophosphamide
[19, 20], which is a similar regimen to other acute SLE
crises such as lupus nephritis. Intravenous immunoglobulins
[21] have been used in one or two case reports with some
success, but the overwhelming treatment goal should be
rapid immunosuppression whatever the method.
After treatment of the acute phase, there seems to be no
real consensus on what is the appropriate long-term drug
choice, with steroids and azathioprine among the choices
[22].
When there is secondary antiphospholipid syndrome,
a recent consensus statement suggests warfarin in the case
of symptomatic valvulopathy, thrombus, and pulmonary
hypertension only and not as a routine [23].
8.5.2. Resynchronisation Therapy. One potential therapeutic
option in advanced stages of heart failure regardless of the
source is cardiac resynchronisation therapy (CRT). There
have been several reports illustrating the successful use of
cardiac resynchronization in patients with SLE and resistant
cardiomyopathy [24, 25]. As yet there is much discus-
sion about which patients beneﬁt from resynchronisation,
but while there is not complete agreement about patient
selection, most groups agree that those with ventricular
dyssynchrony, reduced ejection fraction, and symptomatic
N e wY o r kc l a s s i ﬁ c a t i o n2t o3h e a r tf a i l u r eb e n e ﬁ tm o s t[ 26].
Oneinteresting potential unexpectedbeneﬁtofCRTisthatit
has been shown to reduce inﬂammatory cytokines, possibly
reducing the inﬂammatory process [27].
Overall SLE myocarditis has a much poorer outcome
when compared to primary myocarditis [28], and this
illustrates the need for prompt diagnosis and early aggressive
treatment, which can result in improvement of myocardial
function back to normal [19].
8.6. Cardiac Transplant in SLE. Our search results revealed
a total of 7 cases of cardiac transplant in SLE for a variety
of reasons, 4 were for pulmonary hypertension, 1 for post-
mitral valve replacement heart failure, 1 for cardiac failure
following prolonged infective endocarditis in a patient with
SLE, and 1 patient with myocarditis and heart failure [29,
30]. Transplant was successful in 5 of the seven cases with
followup through both cohorts being at least 14 months
[29, 30], and in the case of the patient with myocarditis
18 months with no signs of recurrence on endomyocardial
biopsy and EF of 50–60% [30].
While these are small numbers, they do, at least, give
some guidance to physicians that in refractory cases trans-
plant is an option and that there have been positive results in
thesmallnumberofpatientsthathavebeenoperatedon.The
ideal postoperative combination of antirejection treatment is
normally decided by the local transplant team involved, but
intheseries,thatwereviewedthatcyclosporin,prednisolone,
and azathioprine in combination was the most widely used
regimen [30, 31].
9. Conclusions
Cardiac SLE is a complex disease with multiple possible
pathological processes that requires prompt investigation
and prompt treatment, otherwise the damage is unrecover-
able as proven in our patient.
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